techwiki

argenx

Founded in 2008 and listed on NASDAQ and Euronext Brussels, argenx is one of Belgium's most successful biotech companies by market capitalization. The company focuses on developing treatments for severe autoimmune diseases using its proprietary antibody technology platform, SIMPLE Antibody. Its lead product, efgartigimod, is approved in multiple markets for myasthenia gravis and several other indications.

Stated facts & numbers

  • Argenx pays $2.2 billion for Forte Biosciences, a US biotech with no drug on the market; its key asset FB-102 is still in early testing phase. (0:09:14, De Tijd 2026-07-28)
  • Vyvgart has become a commercial machine generating billions of euros per year for Argenx. (0:10:45, De Tijd 2026-07-28)
  • Alphabet and Tesla report earnings Wednesday, SAP Thursday, Volkswagen Friday, and Argenx Thursday morning; Sofina reports half-year results on 2 September. (0:12:54, De Tijd 2026-07-20)
  • Euronext mini options require only 10 shares (versus 100 for standard contracts) and exist on ASML, Argenx, UCB and — exceptionally at 1 share — Lotus Bakeries. (0:41:09, De Tijd 2026-06-24)

Who works here6

Open positions

All 12

Recent mentions8